Last reviewed 2026-04-20 · How we verify

RIZATRIPTAN BENZOATE

Rizatriptan treats migraines by binding to 5-HT 1B/1D receptors on blood vessels and nerves.

Rizatriptan benzoate is a marketed drug for the acute treatment of migraines, with a key composition patent expiring in 2028. Its mechanism of action, targeting 5-HT 1B/1D receptors, provides a strong therapeutic profile for migraine relief. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Mechanism of action

Rizatriptan works by binding to specific receptors called 5-HT 1B/1D receptors. These receptors are found on blood vessels in the head and on sensory nerves of the trigeminal system, which are involved in migraine pain. By binding to these receptors, Rizatriptan helps reduce inflammation and constricts blood vessels, alleviating migraine symptoms.

Approved indications

• Acute treatment of migraine

Common side effects

• Atypical Sensations
• Paresthesia
• Pain and other Pressure Sensations
• Chest Pain: tightness/pressure and/or heaviness
• Neck/throat/jaw: pain/tightness/pressure
• Regional Pain: tightness/pressure and/or heaviness
• Pain, location unspecified
• Digestive
• Dry Mouth
• Nausea
• Neurological
• Dizziness

Drug interactions

• Propranolol
• Ergot-Containing Drugs
• Other 5-HT1 Agonists
• SSRIs/SNRIs
• Monoamine Oxidase Inhibitors (MAO-A and non-selective)

Key clinical trials

• A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache (PHASE4)
• Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072) (PHASE3)
• Study to Test an Approved Product in the Early Treatment of Migraine (0462-066) (PHASE3)
• Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071) (PHASE3)
• Study to Test an Approved Product in the Early Treatment of Migraine (0462-065) (PHASE3)
• A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis (PHASE3)
• Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081) (PHASE3)
• A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.